Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 80.0%

Neg 0% Neu 80% Pos 0%

Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.